Lilly Sees More Dealmaking as GLP-1 Wins Expand Market
Eli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
We compare Which Dividend Aristocrats Etf Did Best In 2024, spotlighting performance leaders and factors behind stronger returns.
23,392 articlesEli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
A high-profile health story meets everyday budgeting: how GLP-1 treatments can impact your finances, with lessons fro...
Palantir emphasizes software-driven AI workflows with an asset-light model, while Oracle bets on cloud-scale GPU depl...
June brings a pivotal AI stock showdown between AMD and Nvidia. This guide breaks down how to evaluate which offers b...
SanDisk and Western Digital surged about 6% in early trading as investors bank on strong AI storage demand and improv...
Homeowners hold trillions in tappable equity, yet tapping that wealth often requires debt. A new option, the home equ...
On a volatile trading day, SpaceX headlines helped ease Nasdaq losses while the Dow pressed onward. Dive into what sp...
China’s domestic auto market is feeling the squeeze even as exporters push ahead. Nio sits at a crossroads where poli...
SpaceX just shook the investor world again with a massive bond offering. This article breaks down what spacex's fundr...
Late-career workers who enroll in Medicare while still employed and continue HSA deposits risk a 6% annual excise tax...
Tesla claims a fleet powered by 2 million mobile cameras to train its AI, while Alphabet’s Waymo expands paid driverl...
The BIS warns that AI-driven hype could trigger a stock-market pullback and spill into credit markets, threatening gl...